Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
AVITA Medical, Inc. RCEL
$12.45
-$2.59 (-20.78%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
387008784.00000000
-
week52high
16.89
-
week52low
4.41
-
Revenue
34421000
-
P/E TTM
-14
-
Beta
0.95343500
-
EPS
-1.13000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 20:00
Описание компании
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | 02 мар 2021 г. | |
| BTIG | Buy | Buy | 25 ноя 2020 г. |
| B of A Securities | Buy | 25 ноя 2020 г. | |
| B of A Securities | Buy | 27 авг 2020 г. | |
| BTIG | Buy | Buy | 09 июл 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| COOK JEREMY CURNOCK | A | 5395 | 5395 | 12 дек 2022 г. |
| COOK JEREMY CURNOCK | A | 16939 | 12589 | 12 дек 2022 г. |
| CORBETT JAMES | A | 226296 | 226296 | 12 дек 2022 г. |
| Crowe Suzanne | A | 5395 | 5395 | 12 дек 2022 г. |
| Crowe Suzanne | A | 21051 | 12589 | 12 дек 2022 г. |
| Panaccio Lou | A | 5395 | 5395 | 12 дек 2022 г. |
| Panaccio Lou | A | 31031 | 12589 | 12 дек 2022 г. |
| REED JAN STERN | A | 5395 | 5395 | 12 дек 2022 г. |
| REED JAN STERN | A | 25614 | 12589 | 12 дек 2022 г. |
| PERRY MICHAEL S | D | 0 | 150000 | 21 ноя 2022 г. |
Новостная лента
Avita Medical Inc. (RCEL) Stock Jumps 6.2%: Will It Continue to Soar?
Zacks Investment Research
30 янв 2023 г. в 06:01
Avita Medical Inc. (RCEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AVITA Medical: Experienced CEO Taking The Helm As Expansion Opportunities Await
Seeking Alpha
23 янв 2023 г. в 05:02
Shares have fallen by 83% over the past 3 years and are down 13% over the past year. Q3 "beat and raise" along with appointment of a highly experienced CEO could turn sentiment around here.
AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call
GlobeNewsWire
19 янв 2023 г. в 16:05
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical” or the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today changes to its management structure designed to advance its strategic growth plans and accelerate execution under recently appointed Chief Executive Officer, James Corbett. To align with AVITA Medical's new operating structure, the following organizational changes will be effective January 19, 2023:
Avita: Micro-Cap With Big Time Approvals On Near Horizon
Seeking Alpha
17 дек 2022 г. в 09:00
Avita has a modest existing business selling its skin regeneration products. Its shares have dropped recently despite several successes with the FDA.
AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference
GlobeNewsWire
21 ноя 2022 г. в 16:01
VALENCIA, Calif., and MELBOURNE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that its management team will present at the Piper Sandler 34th Annual Healthcare Conference in New York on Wednesday, November 30, 2022, at 4:30 p.m. Eastern Time.